Mr. Li Yuhui has been named to the "Forbes China Top 100 Venture Capital Investors" list for eight consecutive years. He has over 25 years of investment experience in China's venture capital and capital markets, with a long-term focus on technology-driven innovation.

In early 2010, Mr. Li founded Pulin Capital and has since led the firm to focus on early- to mid-stage investments in two major sectors — Healthcare & Bio-tech and AI & Technology — achieving outstanding investment performance.

In the early-stage investment space, Mr. Li lead investments in healthcare companies such as Kangtai Bio (300601), Hybribio (300639), Ribo Life Science (06938.HK), Endocell and Virogin, as well as AI and technology companies including Passiontec (fully acquired by Meituan（03690.HK）) , PPIO , O-Cubes ，Ruiyun Cold Chain and Easy-Logic Technology.

In the growth-stage investment space, Mr. Li invested in A-share listed companies such as Toread (300005), Eastern Pioneer (603377), BGE (603588), Sun Shine (acquired by Royal Group, 002329), and XGIMI (688696).

Prior to founding Pulin Capital, Mr. Li worked for over 10 years at top-tier domestic investment banks including former Jun'an Securities and Guotai Junan Securities, where he gained extensive expertise in investment banking services and management. Before that, he spent three years engaged in CAD technology development at a large state-owned enterprise.

Mr. Li graduated from Huazhong University of Science and Technology, Southwestern University of Finance and Economics, and Tsinghua University, holding a Bachelor of Engineering in Mechanical Engineering, a Master of Economics in Finance, and an Executive MBA from Tsinghua University.